Patients share experiences of confusion, fear and fragmented care in managing pregnancies at risk for hemolytic disease of the fetus and newborn (HDFN) or fetal neonatal alloimmune thrombocytopenia (FNAIT) under… Read More
NORTH CHICAGO, Ill. – AbbVie announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the feasibility of dosing and monitoring patients in the outpatient setting for the first… Read More
Vancouver, BC – Kardium Inc., a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), announced it has received pre-market approval (PMA) for the Globe® Pulsed Field… Read More
VANCOUVER, BC – Zymeworks Inc. a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and… Read More
Positive results were observed across all subgroups Study meets several key secondary endpoints with statistical significance SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. – United Therapeutics Corporation, a public benefit… Read More
